Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation

(2010) Evan Y. Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

(2009) Fernando E.C. Calais da Silva et al.   EUROPEAN UROLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

(2009) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study

(2008) Jacques Irani et al.   EUROPEAN UROLOGY

The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer

(2008) Martin Gleave et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer

(2008) Bostjan Seruga et al.   Nature clinical practice. Oncology